Income Statement (Annual)

HCOM / Hawaiian Telcom Holdco, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Revenues 395,156 385,498 391,150 390,739 393,413 392,963 368,419
Costs And Expenses
  Gain Loss On Disposition Of Property - - - - - - -
  Cost Of Revenue 159,822 160,226 163,749 166,280 162,474 - -
  Selling General And Administrative Expense 120,390 108,508 114,875 115,974 123,798 118,420 114,893
  Depreciation Depletion And Amortization 63,806 70,908 77,301 78,014 87,879 89,916 88,424
  Gain Loss On Disposition Of Assets - - 6,546 - - - -
  Costs And Expenses 344,018 339,642 349,379 360,268 374,151 374,171 366,418
Operating Income Loss 51,138 45,856 41,771 30,471 19,262 18,792 2,001
Nonoperating Income Expense
  Interest Expense 25,339 22,183 18,875 16,496 16,786 17,095 16,414
  Gain Loss On Derivative Instruments Net Pretax - - - - - - -
  Gains Losses On Extinguishment Of Debt - -5,112 -3,660 - - - -4,826
  Other Nonoperating Income Expense 65 59 34 34 -19 - -
  Nonoperating Income Expense -25,274 -27,236 -22,501 -16,462 -16,805 -17,095 -21,240
Income Loss From Continuing Operations Before Reorganization Items And Income Taxes 25,864 18,620 19,270 - - - -
Reorganization Items 1,050 - - - - - -
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments 24,814 18,620 19,270 14,009 2,457 - -
Income Tax Expense Benefit -1,341 -91,362 8,782 5,910 1,357 591 88,002
Net Income Loss Available To Common Stockholders Basic 26,155 109,982 10,488 8,099 1,100 1,106 -107,241
Earnings Per Share
  Earnings Per Share Basic 0 0 0 0 0 0 -0
  Earnings Per Share Diluted 0 0 0 0 0 0 -0
Weighted Average Number Of Shares Outstanding
  Weighted Average Number Of Shares Outstanding Basic 10,148 10,243 10,337 10,591 10,977 11,503 11,573
  Weighted Average Number Of Diluted Shares Outstanding 10,844 10,661 11,094 11,308 11,386 11,556 11,573

Peers - Communications Services, Not Elsewhere Classified (4899)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 420031106